Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Diabetic Gastroparesis in 12 Major Markets
Gastroparesis is a syndrome characterised by delayed gastric emptying in the absence of mechanical obstruction. There is no official classification criterion upon diagnosis. Diabetic gastroparesis affects patients with long-standing diabetes mellitus usually complicated with retinopathy, neuropathy and nephropathy.
This report provides the current prevalent population for Diabetic Gastroparesis across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, Brazil, India, China, and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Diabetic Gastroparesis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
These gastrointestinal symptoms include:
• Nausea
• Early satiety
• Bloating
• Postprandial fullness
• Upper abdominal pain
• Vomiting
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Diabetic Gastroparesis market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Diabetic Gastroparesis and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Diabetic Gastroparesis prevalent population.
• Identify sub-populations within Diabetic Gastroparesis which require treatment.
• Gain an understanding of the specific markets that have the largest number of Diabetic Gastroparesis patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Methodology for quantification of patient numbers
o Type 1 Diabetes
o Type 2 Diabetes
o Diabetic Gastroparesis
• Top-line Prevalence for Diabetic Gastroparesis
• Patients with Type 1 Diabetes
o Gastroparesis Symptoms
• Patients with Type 2 Diabetes
o Gastroparesis Symptoms
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Prevalence of diabetic gastroparesis, total (000s)
• Prevalence of diabetic gastroparesis, males (000s)
• Prevalence of diabetic gastroparesis, females (000s)
• diabetic gastroparesis patient with T1DM, total (000s)
• T1 DM diabetic gastroparesis with nausea, total (000s)
• T1 DM diabetic gastroparesis with early satiety, total (000s)
• T1 DM diabetic gastroparesis with bloating, total (000s)
• T1 DM diabetic gastroparesis with postprandial fullness, total (000s)
• T1 DM diabetic gastroparesis with upper abdominal pain, total (000s)
• T1 DM diabetic gastroparesis with vomiting, total (000s)
• Diabetic gastroparesis patients with T2DM, total (000s)
• T2 DM diabetic gastroparesis with nausea, total (000s)
• T2 DM diabetic gastroparesis with early satiety, total (000s)
• T2 DM diabetic gastroparesis with bloating, total (000s)
• T2 DM diabetic gastroparesis with postprandial fullness, total (000s)
• T2 DM diabetic gastroparesis with upper abdominal pain, total (000s)
• T2 DM diabetic gastroparesis with vomiting, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of T1DM by 5-yr age cohort, total (000s)
• USA Prevalence of T2DM by 5-yr age cohort, total (000s)
• Canada Prevalence of T1DM by 5-yr age cohort, total (000s)
• Canada Prevalence of T2DM by 5-yr age cohort, total (000s)
• France Prevalence of T1DM by 5-yr age cohort, total (000s)
• France Prevalence of T2DM by 5-yr age cohort, total (000s)
• Germany Prevalence of T1DM by 5-yr age cohort, total (000s)
• Germany Prevalence of T2DM by 5-yr age cohort, total (000s)
• Italy Prevalence of T1DM by 5-yr age cohort, total (000s)
• Italy Prevalence of T2DM by 5-yr age cohort, total (000s)
• Spain Prevalence of T1DM by 5-yr age cohort, total (000s)
• Spain Prevalence of T2DM by 5-yr age cohort, total (000s)
• UK Prevalence of T1DM by 5-yr age cohort, total (000s)
• UK Prevalence of T2DM by 5-yr age cohort, total (000s)
• Brazil Prevalence of T1DM by 5-yr age cohort, total (000s)
• Brazil Prevalence of T2DM by 5-yr age cohort, total (000s)
• Japan Prevalence of T1DM by 5-yr age cohort, total (000s)
• Japan Prevalence of T2DM by 5-yr age cohort, total (000s)
• India Prevalence of T1DM by 5-yr age cohort, total (000s)
• India Prevalence of T2DM by 5-yr age cohort, total (000s)
• China Prevalence of T1DM by 5-yr age cohort, total (000s)
• China Prevalence of T2DM by 5-yr age cohort, total (000s)
• Russia Prevalence of T1DM by 5-yr age cohort, total (000s)
• Russia Prevalence of T2DM by 5-yr age cohort, total (000s)
